Hepatorenal syndrome secondary prevention: Difference between revisions
Jump to navigation
Jump to search
(Created page with "__NOTOC__ {{Hepatorenal syndrome}} {{CMG}} ==Overview== ==Secondary Prevention== ===Intravenous albumin=== A randomized controlled trial found that intravenous albumin on...") |
|||
| (4 intermediate revisions by 2 users not shown) | |||
| Line 1: | Line 1: | ||
__NOTOC__ | __NOTOC__ | ||
{{Hepatorenal syndrome}} | {{Hepatorenal syndrome}} | ||
{{CMG}} | {{CMG}}; {{AE}}{{SKA}} | ||
==Overview== | ==Overview== | ||
The use of [[albumin]] helps improvement of HRS. | |||
==Secondary Prevention== | ==Secondary Prevention== | ||
===Intravenous albumin=== | ===Intravenous albumin=== | ||
A [[randomized controlled trial]] found that intravenous albumin on the day of admission and on hospital day 3 can reduce | A [[randomized controlled trial]] found that intravenous [[albumin]] on the day of admission and on hospital day 3 can reduce [[Renal insufficiency|renal impairment]].<ref name="pmid10432325">{{cite journal |author=Sort P, Navasa M, Arroyo V, ''et al'' |title=Effect of intravenous albumin on renal impairment and mortality in patients with cirrhosis and spontaneous bacterial peritonitis |journal=N. Engl. J. Med. |volume=341 |issue=6 |pages=403-9 |year=1999 |pmid=10432325 |doi=}}</ref> | ||
'''Pentoxifylline''' | |||
[[Pentoxifylline]], [[Phosphodiesterase inhibitors|phosphodiesterase inhibitor]] improves [[kidney]] functioning status in patients of hepatorenal syndrome.<ref name="pmid104323252">{{cite journal| author=Sort P, Navasa M, Arroyo V, Aldeguer X, Planas R, Ruiz-del-Arbol L et al.| title=Effect of intravenous albumin on renal impairment and mortality in patients with cirrhosis and spontaneous bacterial peritonitis. | journal=N Engl J Med | year= 1999 | volume= 341 | issue= 6 | pages= 403-9 | pmid=10432325 | doi=10.1056/NEJM199908053410603 | pmc= | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=10432325 }}</ref> | |||
==References== | ==References== | ||
{{Reflist|2}} | {{Reflist|2}} | ||
[[Category: | [[Category:Hepatology]] | ||
[[Category:Gastroenterology]] | [[Category:Gastroenterology]] | ||
[[Category:Nephrology]] | [[Category:Nephrology]] | ||
Latest revision as of 15:08, 22 December 2017
|
Hepatorenal syndrome Microchapters |
|
Diagnosis |
|---|
|
Treatment |
|
Case Studies |
|
Hepatorenal syndrome secondary prevention On the Web |
|
American Roentgen Ray Society Images of Hepatorenal syndrome secondary prevention |
|
Risk calculators and risk factors for Hepatorenal syndrome secondary prevention |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Sunny Kumar MD [2]
Overview
The use of albumin helps improvement of HRS.
Secondary Prevention
Intravenous albumin
A randomized controlled trial found that intravenous albumin on the day of admission and on hospital day 3 can reduce renal impairment.[1]
Pentoxifylline
Pentoxifylline, phosphodiesterase inhibitor improves kidney functioning status in patients of hepatorenal syndrome.[2]
References
- ↑ Sort P, Navasa M, Arroyo V; et al. (1999). "Effect of intravenous albumin on renal impairment and mortality in patients with cirrhosis and spontaneous bacterial peritonitis". N. Engl. J. Med. 341 (6): 403–9. PMID 10432325.
- ↑ Sort P, Navasa M, Arroyo V, Aldeguer X, Planas R, Ruiz-del-Arbol L; et al. (1999). "Effect of intravenous albumin on renal impairment and mortality in patients with cirrhosis and spontaneous bacterial peritonitis". N Engl J Med. 341 (6): 403–9. doi:10.1056/NEJM199908053410603. PMID 10432325.